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EFFICACY OF DERMABRASION ALONG WITH 1% 
TOPICAL     5 FLUOROURACIL IN 25 PATIENTS OF 
VITILIGO. 
 
ABSTRACT : 
BACKGROUND :Vitiligo is a common pigmentary disorder of the skin 
with much  prejudice and taboos.Various therapeutic approaches are 
available at present, which includes topical and systemic steroids, photo 
chemotherapy with psoralens, narrow band UVB  therapy,  and calcineurin 
inhibitors. In addition to medical therapies various surgical procedures are 
available for patients with stable vitiligo. Among the various surgical 
modalities, therapeutic dermabrasion   with topical 5- fluorouracil 
application over stable vitiligo patch had shown good results in a short 
duration  in various studies, either alone or in combination and seems to be  
have less side effects.AIM OF THE STUDY :To evaluate the efficacy of 
dermabrasion with topical 1%   5-fluorouracil in patients with stable vitiligo 
patches and to assess the feasibility of this procedure in day to day practice. 
METHODOLOGY : This was   one year prospective study  done on twenty 
five patients  attending  Department of  Dermatology at  Coimbatore 
Medical College Hospital, Coimbatore .Both men and women of  age 
ranging from 15-60 years of with clinical diagnosis of stable vitiligo of more 
than 2 year duration were included in the study. Patients  with actively 
spreading vitiligo , those with  acrofacial and  mucosal vitiligo, pregnant  
and lactating women , childrens, diabetic patients,  those currently 
undergoing other topical or systemic therapy for vitiligo, patients with  
history of  keloidal tendency  ,bleeding diathesis  and koebner phenonmenon 
were excluded  from the study. The procedure of dermabrasion with topical 
5 fluorouracil was done for these patients in  first 6 months ,with follow up 
of the patient for next 6 months. RESULT: At the at the end of 6 months, 
out of 25 patients 4  did not turn for   follow up. Partial repigmentation was 
observed in  six patients (28.6%) and  total repigmentation in fifteen   
patients(71.4%). CONCLUSION: Dermabrasion along with topical 5 
fluorouracil can be used as a simple office procedure, in repigmenting 
localised stable vitiligo, which is very economical & brings early 
regimentation without any significant side effects.  
 Key words :  Dermabrasion ,5 Fluorouracil, stable vitiligo.   
   
 
INTRODUCTION 
 
              Vitiligo is a common pigmentary disorder of the skin with much 
prejudice and taboos. Most of the time confused with leprosy and brings 
embarrassment for the patient even though the life expectancy remains 
unaffected.
 
  
 
             The exact etiology of the disease is not known. Various therapeutic 
approaches are available at present, which includes topical and systemic  
steroids, photo chemotherapy with psoralens, narrow band UVB therapy, 
immuno modulators and calcineurin inhibitors. 
 
 In addition to medical therapies various surgical procedures are 
available for patients with stable vitiligo since 1964. 
 
In case of vitiligo, there is a partial or total destruction of melanocytes. 
The prime aim of various medical and surgical therapies is activation of the 
reservoir melanocytes of hair follicle.  
 
The main aims of the surgical procedures are:
1 
 
• The melanocyte stimulation resulting in proliferation, migration and re-
pigmentation from the hair follicles towards the lesion.   
• Introduction of artificial pigments into the lesions. 
• Repopulation of the depleted melanocytes by various grafts. 
 
Among the various surgical modalities, therapeutic dermabrasion with 
topical 5- fluorouracil application over stable vitiligo patch had shown good 
results in a short duration  in various studies, either alone or in combination and 
seems to be  have less side effects. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Review of Literature 
REVIEW OF LITERATURE 
 
VITILIGO: 
 Vitiligo is an idiopathic, acquired, circumscribed hypomelanotic skin 
disorder, characterized by milky white patches of different sizes and shapes and 
affects 1-2% of the world population. 
2, 3
 
Historical Aspects: 
 The earliest reports on patchy skin diseases date back approximately 
1500 BC. The Roman physician Celsus was the first to coin the term Vitiligo in 
his Latin medical classic De Medicina in 1st century AD. El  Mofty suggests 
that vitiligo is derived from the Latin word ‘Vitelius’ which means ‘calf’ 
referring to the characteristic white patches of the disease resembling the white  
patches of a spotted calf.
 5
 Other authors however believe that the term is 
derived from the Latin word‘vitium’ meaning a fault or blemish. 
4
 
  The Ancient Indian sacred book, ‘Atharva Veda’ reports on the disease 
in the name called” kilas “meaning “white “The Indian Manu Smirti (200BC) 
describes “Sweta Kushta “  meaning white disease which probably represents 
vitiligo.
 5
 
In Bible the white spots were described in the Old Testament under the 
Hebra word ‘Zora at’, and this word was translated as ‘lepra’ in the Greek. 
6
 
  In South India, vitiligo is still called ‘Ven Kushtam’ translated as ‘white 
leprosy’. As the social stigma makes patient conceal their white spots, even 
today in the Indian Villages, the disease is often called ‘Charak’ meaning ‘the 
secret disease’. 
 
 
 
EPIDEMIOLOGY 
 Vitiligo is relatively common disorder affecting all races around the 
world. 
7 
Even though it does not show sexual predilection the female 
prevalence in some studies probably has been attributed to the greater concern 
about their cosmetic defect. 
8 
Its incidence varies between 1-2% over the world 
population. 
9
 
In India, highest number of cases has been reported in the states of 
Gujarat and Rajasthan.
10 
Few dermatological outpatient records shows, 
 the incidence of  vitiligo to be 0.25-2.5% in India .
11
 Vitiligo appears to be 
observed more commonly in darker skin types. 
 The mean age of onset of vitiligo is 25 years for males & 20 years for 
females.
12
About 20% of vitiligo patients have atleast one first degree relative 
with vitiligo. The relative risk for 1 st degree relatives is  7 -10 fold.
13
 
 AETIOPATHOGENESIS 
The etiology of vitiligo is multifactorial with a complex pathogenesis. 
Although several theories have been proposed to explain the loss of epidermal 
melanocytes in vitiligo, the precise cause remains unknown. Considerable 
progress has been made, however over the last two decades. 
GENETIC FACTORS AND INHERITANCE 
Vitiligo is a disease of polygenic origin with incomplete penetrance 
involving multiple genes and environmental triggers. Recently multiple 
susceptibility loci and genetic heterogeneity have been identified. The 
inheritance may involve genes associated with melanin biosynthesis, response 
to oxidative stress, and regulators of autoimmunity. 
 
 The possible HLA associations with vitiligo in more than one study 
include HLA A2, DR4, DR7,  Cw6, HLA DRB1A *04-(DQA1*0302)-
DQB1*0301 and   A25-Cw*0602-DQA1*0302.
 14, 15, 16 
 A positive family history has been observed in 30-40% of vitiligo 
patients suggesting a genetic basis for this disorder.
17
 It has also been reported 
in monozygotic twins. 
 
 Several susceptibility genes have now been identified, including loci in 
the MHC, PTPN22, and NALP1 for generalized vitiligo vulgaris.  One of the 
best candidate gene identified, known as FOXD3 (“Forkhead box” D3) located 
on chromosome 1 (1p32–p31) is a transcription factor that suppresses 
melanoblast development from the neural crest 
[18].
 when dysregulated  in the 
form overexpression might harm melanocytes.  
 
THEORIES ON THE PATHOGENESIS: 
Many factors play a role in etiopathogenesis in addition to genetic 
predilection. Traditionally there have been three hypotheses to explain           
vitiligo.
 19
  
1. Autoimmune Theory  
2. Neural Hypothesis  
3. Self destructive Theory  
1. AUTOIMMUNE THEORY 
This is most popular hypothesis proposed   for pathogenesis of vitiligo it 
states that melanocytes are killed by autoimmune effector mechanism, probably 
there may be some kind of biochemical trauma to melanocytes resulting in the 
release of some antigenic substances and subsequent auto immunization or 
there may be certain immune cells directed against antigenic components of 
autologous melanocytes. 
 
 The various evidences to suggest autoimmune hypothesis are 
• The clinical association of vitiligo with a number of  auto immune 
disorders  like autoimmune Thyroid disease ,Diabetes mellitus, 
Pernicious anaemia, Addison’s disease, Hypoparathyroidism, 
Myasthenia  gravis and Alopecia areata  
20,21,22  
 . 
• Generalized vitiligo is a component of the APECED (APS1) and 
Schmidt (APS2) multiple autoimmune disease syndromes. 
Role of  Humoral immunity 
• Several circulating autoantibodies to non-pigment cell antigens 
(common tissue antigens), cytoplasmic pigment cell antigens, and 
pigment cell surface antigens 
23
 have been found in sera of vitiligo 
patients.  
• Organ-specific autoantibodies to  thyroid, gastric parietal cells and  
adrenal tissue are found in the serum more frequently in patients with 
vitiligo than in the general population 
• A complement-fixing antibody to melanocytes has been found in the 
serum of  several patients who in addition to vitiligo had alopecia areata,  
mucocutaneous  candidiasis and multiple endocrine insufficiencies   
• Antimelanocyte antibody dependent cellular cytotoxicity and 
complement mediated lysis have been noted in vitiligo patient.
 24
 
•
 Injections of serum IgG fractions from patients with vitiligo found to 
have a destructive effect on melanocytes of the human skin grafted onto 
nude mice.
25  
• The serum level of  auto antibodies was found to correlate with the 
disease activity and the extent of the cutaneous depigmentation 
 
 
Role of Cell mediated immunity 
In a recent study on skin lesions of vitiligo a high frequency of 
cutaneous lymphocyte antigen-positive-activated cytotoxic T-cells clustered in 
perilesional skin in the vicinity of disappearing melanocytes have been               
noted
. 26
 
Increased levels of CD45RO memory T-cells, soluble interleukin-2 
receptors and expression of the cutaneous lymphocyte antigen in infiltrating T-
cells, suggest an activation of circulating T-cells and their recruitment to the 
vitiligo skin
.
 
27, 28, 29
  
Immunotherapy of melanoma with high-dose IL-2 therapy, infusion of 
peptide pulsed dendritic cells, and MelanA/MART-1 specific CTL clones 
30
 
produced vitiligo-like depigmentation suggesting a cytotoxic T cell activity 
over melanocytes. 
2. NEURAL HYPHOTHESIS  
       This hypothesis suggests that destruction of melanocytes may occur 
because of liberation of some unusual neurochemical mediator or due to a gross 
alteration in the ratio of the normal neurotransmitter substances in the lesion.  
Evidences in favour of neural hypothesis include 
• Occurrence of Vitiligo in neurologically compromised skin, following 
peripheral nerve injury, with multiple sclerosis , following viral 
encephalitis, with Horner’s Syndrome, and among emotionally hyper 
stressed and psychiatric patients.
31, 32
 
• Dermatomal distribution of segmental vitiligo. 
• An increased immunoreactivity of neuropeptide (NYP) or an altered 
balance of nerve growth factor receptors and calcitonin gene related 
peptide has been observed in vitiligo  
• The common embryologic origin of melanocytes and the nervous 
system. 
• Demonstration of direct contact between cutaneous free nerve endings 
and epidermal melanocytes in vitiligo macules. 
• Repigmentation in segmental lesions was observed by administration of 
nilamide, an oral monoamine oxidase inhibitor, to suppress metabolism 
of catecholamines at the sympathetic nerve endings. 
3. SELF DESTRUCTIVE THEORY  
 This theory suggests that precursors or metabolites of the melanogenesis 
are toxic to melanocytes. Melanocytes may possess an intracellular protective 
mechanism to eliminate toxic melanin precursors (e.g. dopa, dopachrome, and 
5.6dihydroxyindole)) and free radicals. In case of vitiligo, there might be a 
disturbance of this mechanism,, leading to an accumulation of indoles and free 
radicals causing destruction  of melanocytes.
33 
 One other possible mechanism could be damage to the membranes of 
melanosomes by genetic mechanisms or by perioxidation 
34,
 which prevent 
leakage of these compounds into the cellular milieu 
35, 36
 causing destruction of 
melanocytes. 
OTHER HYPOTHETICAL THEORIES 
• MELANOCYTE GROWTH FACTOR REDUCTION HYPOTHESIS 
Depigmentation in vitiligo may be due reduced local and circulating 
levels of growth factor responsible for normal proliferation and maintenance of 
melanocytes.
 37 
• MELANOCYTE DEFECTIVE ADHESION HYPOTHESIS 
Repeated friction in non-lesional skin of vitiligo patients induces 
detachment and transepidermal elimination of melanocytes 
38 
that could have 
been previously damaged by another process,
.39  
suggesting that minor 
mechanical trauma in non-lesional vitiligo skin is probably the cause of 
depigmentation . 
• ANTIOXIDANT DEFICIENT THEORY 
  Melanocyte toxicity   can occur following a breakdown in antioxidant 
defence of epidermis. 
 40 
This theory is supported by the observation in the 
epidermis of vitiligo patients of low levels of catalase activity. This oxidative 
stress could lead to accumulation in skin of high concentrations of 6 and 7 
biopterins which inhibit the tyrosinase activity extremely cytotoxic to 
melanocytes.
 41
 
COMPOSITE HYPOTHESIS  
This hypothesis suggests that vitiligo is not a single disease but involves 
several processes. This includes  
1. Excessive acetyl choline production in skin or decreased 
cholinesterase activity in skin  
2. Process of self destruction caused by metabolites evolved during 
melanin synthesis 
3. An autoimmune phenomenon 
  DISORDER OF MELANOCYTE SURVIVAL 
Several observations suggest the involvement of melanocyte apoptosis 
and the SCF/c-kit/MITF/Bcl-2 pathway in the pathogenesis of vitiligo. 
Decrease in Bcl-2 expression of melanocytes, reduced levels of SCF, down-
regulated expression of c-kit and MITF-M proteins has been reported in the 
perilesional skin of vitiligo patients.
42, 43 
INTRINSIC DEFECT 
An intrinsic defect of the structure and function of rough endoplasmic 
reticulum in vitiligo melanocytes.
44
 
CLINICAL FEATURES 
45
 
             A typical lesion is a well defined depigmented (milky white or chalky) 
macule, round to oval in shape, showing a variable number of depigmented 
(white) hairs, without any change in the skin texture. In many cases the margin 
is hyperpigmented. 
  The location of individual macules, their number, size and shape varies 
widely. The initial macules usually occur on the exposed areas (such as the 
dorsal surface of hands, elbows, feet, legs, knees, neck and face), body folds 
(such as axillae, groin, and sub mammary region in women), lips and genitalia. 
Involvement of pretibial region, palms and sole are quite common in India.
 
 
 In the covered areas, the initial lesion is commonly noted on the chest 
wall, lower back or areola and the lesion may be one or more macules widely 
varying in size and shape. Distribution is generally more or less symmetrical 
when lesions occur bilaterally.  
 In some cases almost total depigmentation of body surface may develop 
slowly or rapidly with only a few or no islands of normal pigmentation. The 
lesions enlarge by invading the normally pigmented surrounding skin, which 
assumes a concave shape at the border. Virtually no area of skin is exempted.  
 The initial unifocal lesion may be followed by the appearance of new 
lesions elsewhere. In less than 25% of cases the onset may be multifocal. Onset 
of the lesions is usually insidious. The disease is usually progressive in nature 
but the course is virtually unpredictable. 
 While some lesions may show signs of repigmentation, new lesions may 
develop on other parts of the body simultaneously. There is an episodic phase 
of rapid extension of lesions after remaining quiescent over a long period of 
time. 
Koebner’s phenomenon is seen in 6-20% of cases of vitiligo Vulgaris.
 46 
Minor trauma such as scratch mark, laceration, or stitches on the skin results in 
the development of a corresponding linear depigmented macule, usually in 2-4 
week. 
Morphological variations on the typical vitiligo macule.
 47
 
• Trichrome vitiligo: characterized by hypopigmented and depigmented 
macule in addition to normally pigmented skin. 
• Quadrichrome vitiligo:besides the three colours of trichrome vitiligo.  
Here the fourth colour  is macular perifollicular or marginal 
hyperpigmentation.  
• Pentachrome vitiligo: blue-gray hyperpigmentation in addition to four 
colours of quadrichrome vitiligo representing melanin incontinence. 
• Blue vitiligo corresponds to vitiligo macules occurring in sites of post 
inflammatory hyperpigmentation. 
• Inflammatory vitiligo has an erythematous, raised border. 
• Confetti macules or vitiligo ponctue: these are tiny discrete 
hypomelanotic macules that may occur randomly or it may be 
perifollicular.  
• Valeceo’ type of vitiligo: very sudden rapid onset, extension and spread 
of lesion following emotional trauma and repression. 
 
 
 
 
 
 
Classification of vitiligo (according to Ortonne, 1983)
 48
 
Localized vitiligo Generalized vitiligo Universal vitiligo 
1.. Focalis; only one or 
more depigmented 
macules  not  
in a segmental or 
zosteriform 
distribution 
 
2.. Segmental: one or more 
macule in a  
quasidermatomal pattern 
 
3.. Mucosalis: only mucous 
membrane(s) affected  
 
Acrofacial: Distal 
extremities and face  
 
 
 
 
 
 
 
 
 
Vulgaris: scattered 
macules over the 
entire body with a 
symmetrical 
distribution pattern  
 
Mixed :Acrofacialis 
and/or vulgaris 
and/or segmentalis 
Universalis: > 80 % 
depigmentation 
 
 
 
 
 
 
Clinical Types of Vitiligo 
49
 
• Generalized vitiligo / Vitiligo vulgaris: This is the most common type 
of vitiligo and is characterized by few to many widespread macules. 
These macules are often symmetrically placed and involve extensor 
surfaces of the trunk, extremites, periorificial areas and mucous 
membranes. 
 
• Focal vitiligo / Vitiligo areata is an isolated macule or a few scattered 
macules, limited in both size and number.  
• Segmental / Dermatomal / Zosteriform Vitiligo: characterized by 
unilateral vitiligenous macules and patches with early age of onset stable 
course, frequent association of leukotrichia ,absence of koebner 
phenomenon, and  less response to PUVA therapy.
 50
 Trigeminal areas 
are involved in > 50% of cases. 
• Acrofacial vitiligo involves distal digits and peri-orificial facial areas. 
• Lip – tip vitiligo:  Periungual involvement occurring with involvement 
of mucous membranes like lips, distal penis and nipples. 
• Vitiligo universalis / Universal vitiligo: widespread vitiligo with  few 
remaining areas  of normal   pigmentation. 
Childhood vitiligo: 
51 
The characteristic features of vitiligo in children are  
• A positive family history,  
• Fewer lesions,  
• Less than 5% of body surface area involvement,  
• Frequent segmental involvement, and  
• Greater difficulty in treatment but relatively better prognosis 
Differential diagnosis:  
• Postinflammatory Hypopigmentation  
• Idiopathic guttate hypomelanosis  
• Indeterminate Hansen  
• Pitryasis Alba  
• Nevus Anemicus  
• Nevus Depigmentosus  
• Chemical Leukoderma  
• Piebaldism    
• Albinism  
• Ash Leaf Macule  
• Halo Nevus 
• Hypopigmented mycosis fungoides 
• Post Kala Azar Dermal Leishmaniasis  
• Hypomelanosis of Ito 
• Waarden Burg’s Syndrome  
• Chediak-Higashi syndrome  
• Woolf’s Syndrome  
• Syphilis & Yaws 
 
 
PRECIPITATING FACTORS: 
Endogenous factors: 
• Genetic factors 
• Physical and emotional stressful events(puberty, pregnancy,  
menopause, febrile illness) 
• Associated internal disorders 
• Associated skin diseases 
 
Exogenous factors: 
• Chemicals( film developers , rubber , quinones  and bleaching  
agents) 
• Drugs (such as beta adrenergic blocking agent) 
52
 
• Physical stimuli (koebner phenomenon): scratching, bumping, 
stubbing, grazes and burn.                                   
COURSE OF THE DISEASE  
The natural course is uncertain, often showing tendency towards slow  
progression. Spontaneous repigmentation is noted in about 10-20% of patients,  
most frequently in un-exposed areas and in younger patients. 
Focal vitiligo, although stable for a time, may be a precursor of 
generalized vitiligo but spontaneous resolution is possible. 
The course of vitiligo vulgaris is often abrupt onset, followed by  
progression for a time,then a period of stability follows and may last for some  
time, even decades. This may be followed later by a period of rapid 
progression. Total spontaneous regression is unusual.  
  Segmental vitiligo slowly progress for a relative period of one year 
and remains stable with little extension or regression. Tendency towards 
spontaneous pigmentation is rare. 
 
 
 PROGNOSIS: 
The following factors usually indicate a poor prognosis: 
1. Lesions on the resistant sites, such as 
• Bony prominences 
• Non fleshy areas 
• Non-hairy areas   
• Mucosal areas 
2. Family H/O vitiligo  
3. Old age  
4. Associated with systemic diseases 
5. Higher percentage of white hairs in the patch 
6. Extensive long standing cases 
7. Injudicious administration of topical and systemic medications particularly  
    chemotherapeutic agents.
 53, 54, 55 
 
Vitiligo disease activity score (VIDA) 
56
 
It is a six-point scale for assessing vitiligo activity and the scoring is 
based on the individual’s own opinion of the present disease activity over time. 
Active vitiligo involves either expansion of existing lesions or appearance of 
new lesions. Grading is as follows:  
+4 – Activity of 6 weeks or less duration; 
+3 – Activity of 6 weeks to 3 months; 
+2 – Activity of 3 - 6 months; 
+1 – Activity of 6 - 12 months; 
 0 - Stable for 1 year or more; and 
-1 - Stable with spontaneous repigmentation since 1 year or more. 
• A low VIDA score indicates less activity. 
• For vitiligo surgeries to be performed, the VIDA score must be 0 or -1 
57
 
 
 
Inflammatory and autoimmune diseases associated with vitiligo 
 
• Thyroid disorders (Hashimotos thyroiditis, Graves’ disease, toxic 
thyroiditis)
 58, 59
 seen in 0.6 % -38% of patients. 
• Diabetes mellitus: occurs in 1 to 1.7% of vitiligo patients and 
conversely, vitiligo occurs in 4.8% of diabetic patients.
60
 
• Alopecia areata 
• Rheumatoid arthritis 
• Addison’s disease 
• Pernicious anaemia 
• Psoriasis 
• Systemic lupus erythematosus 
• Autoimmune Polyendocrine Syndromes 
Rare associations: 
• Lichen Planus. 
• Lichen Sclerosus 
• Urticaria 
• Ichthyosis 
• Malignant Melanoma 
• Human Immunodeficiency Virus Disease 
• Bullous pemphigoid, 
• Dermatitis herpetiformis   
• Twenty nail dystrophy     
• Halo naevi 
 
Associated hair abnormalities: 
• Leukotrichia: Depigmented hairs are found commonly in isolated 
vitiligo macules, it has been reported in 9-45% of vitiligo patients which 
is a marker of poor prognosis  
• Premature gray hair occurs in up to 37% of patients. 
61
 
 
Ocular Abnormalities 
 
Ocular abnormalities include uveitis, iris transillumination defects and 
heterochromia irides retinal pigment epithelium hypopigmentation and 
depigmentation, chorio retinal scars, pigment clumping, retinitis pigmentosa.
62 
 
Vogt-Koyanagi-harada syndrome: (Uveomenigitic syndrome) 
             A rare multisystem disorder with acute onet of severe uveitis, meningo 
encephalitis and deafness, followed by the appearance of poliosis,, alopecia 
areata and vitiligo 
Otic abnormalities 
• Alezzandrini’s syndrome: unilateral retinal degeneration, ipsilateral 
vitiligo, poliosis, and  deafness. 
 
• Sensory neural deafness has been reported in a very few patients with 
vitiligo 
63
 
 
Laboratory evaluation of patients with vitiligo: 
 
Histopathology: 
 
 Histopathological findings in vitiligo differ according to the three phases 
of the disease: 
64, 65
 
(1) Early stage lesions,  
(2) Established lesions and  
3)  Long standing lesions  
 
Early stage lesions:  
Superficial perivascular infiltrate of lymphocytes with a variable number 
of lymphocytes in the lower half of the epidermis is seen. . This can be 
mistaken for a series of other cutaneous inflammatory lichenoid/spongiotic 
disorders. 
 
Established vitiligo:  
There is an absence of pigmentation of the basal epidermal layer.  
Fontana masson silver stain confirms the absence of melanin. 
66
 There may be a 
sparse superficial perivascular infiltrate. Histochemical studies show a loss of 
DOPA-positive melanocytes in the basal layer. 
 
Long-standing lesions:  
A marked absence of melanin in the epidermis is the main finding. 
Inflammatory infiltrates cannot be demonstrated. Degenerative changes are 
seen, besides degenerative changes in nerves and sweat glands. 
 
Progressive lesions:   
The content of melanin in the epidermal basal layer may be either 
reduced or normal. Lymphocytes sometimes can be found in close apposition 
to melanocytes at the advancing edge of the lesion.
67
  
 
Findings in perilesional and distant areas: 
  Focal areas of vacuolar degeneration in the basal layer, in association 
with a mild mononuclear cell infiltrate, have been observed in clinically normal 
pigmented skin adjacent to vitiliginous areas. 
68
 
 
Micro depigmentation: 
Microscopic disappearance of melanocytes, in association with T-cell 
infiltrates in the dermoepidermal junction of the clinically normal- pigmented 
skin in patients with active generalized vitiligo 
68
 has been recently described. 
 
Special stains for melanin 
• Fontana-Masson stain 
• Silver nitrate 
69
 
 
 
The DOPA Reaction:  
On the basis of DOPA reaction vitiligo may be classified as follows: 
70
 
 
Absolute            :  No DOPA positive melanocytes 
Relative type 1 :  Weak DOPA reaction but normal number of melanocytes 
Relative type 2 :  Reduced number of DOPA positive melanocytes 
 
Immunohistochemical staining for melanocytes:  
 
Immunohistochemical stains used for finding melanocytes are S-100 
protein, HMB 45, NKI-beteb  , T311 ,MEL-5(clone TA99) and Melan-A(A-
103)/Mart-1. 
71,72,73
 
 
MANAGEMENT OF VITILIGO 
 
        It can be divided in to Medical therapy and Surgical therapy 
 
Medical therapy includes  
• General measures 
• Topical therapy   and  
• Systemic therapy 
 
GENERAL MEASURES 
• Counselling   the patient regarding the nature of the disease, its course 
and prognosis. 
• Reassurance is essential. 
• Avoidance of precipitating factors. 
TOPICAL THERAPIES 
• Corticosteroids: 
        Mid to super potent steroids can be tried upto 2 to 4 months 
 Interrupted topical therapy: 
      To minimize complication especially for lesions around the 
eyelids, steroid ointment can be applied twice daily for 2 months 
followed by a treatment free period of 2 weeks in cyclical order that can 
be continued for 8 months or longer if there is a response.   
         
• Calcipotriene : 
           Once daily application increases the efficacy of topical steroids. 
  
 
• Tacrolimus ointment: 
         0.1% ointment found to be efficacious mainly in case of mucosal 
vitiligo.   
 
• Topical PUVA: 
        0.05%-0.1% 8-Methoxy Psoralen followed by UVA can be used. 
 
• Human Placental Extract: 
 It is a hydro alcoholic extract of the human placenta 95% 
ethanol.
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 Melagenina should be applied three times a day before 
exposure to ultraviolet light, sunlight or infrared light. The timing of the 
application is said to be critical and must be administered at 8 hour 
intervals. The treatment duration varies between months to as long as 10 
years. 
 
• Basic fibroblast growth factor : 
o Recently developed treatment modality  capable of stimulating  
the  melanocytes from the hair follicles & also act as chemotactic 
agents to direct the new melanocytes to vitiligo patch.
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• Topical application of pseudocatalase and calcium chloride with short 
term UVB used twice a day has been claimed to produce 
repigmentation. 
 • Calcipotriol with PUVA therapy: 
It has been reported to be an effective adjunctive treatment for vitiligo 
enhancing the efficacy of PUVA therapy. 
SYSTEMIC THERAPIES 
 
Photochemotherapy: 
   This is the most widely employed systemic therapy for vitiligo. 
Treatment involves intake of psoralen derivatives or any other photosensitizing 
agent orally, followed by irradiation with Ultraviolet A. 
 
PUVA 
Among the furocoumorin compounds, psoralen is the most effective 
one. The exact mechanism of pigmentation following PUVA is not fully 
known. Increase in number of functional melanocytes; number and size of 
melanosomes, number of dendrites of melanocytes, transfer of melanosomes to 
keratinocytes and tyrosinase activity have been noted. 
TYPES OF PSORALENS 
• TRIMETHYL PSORALEN (TMP) 
• 8 METHOXY PSORALEN  (8-MOP) 
• 5METHOXY PSORALEN 
ORAL PUVA 
Psoralens (8-MOP or TMP) are given in the dose of 0.6mg/kg/day 
followed by exposure to UVA after 1-3 hrs for 2-3 times a week. The treatment 
is started with a initial dose ranging from 0.5 to 5J/cm2 of UVA based upon 
minimal erythema dose or skin type. Subsequently increments of 0.5J/cm2 are 
made till a uniform erythema occurs over the lesions or a total dose of 8J/cm2 
is reached. 
 If sunlight is utilized as a source of UV light the TMP is preferred as it 
is less phototoxic when compared to 8-MOP.
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 If there is no response after 6 
months or 50 treatments, PUVA should be terminated. 
CONTRAINDICATIONS:  
• It should be avoided in less than 12 years of age.  
• Pregnancy 
• Lactation 
• Photosensitivity 
• Radiotherapy 
• Porphyrias 
• Systemic lupus erythematosus. 
Side effects 
• Nausea  
• Pruritus 
• Epigastric tenderness 
• Insomnia  
• Erythema  
• Skin rash 
 
NARROW BAND UVB 
        Narrow band UVB obviates sun burn and phototoxicity produced by 
broadband UVB and it is more effective than PUVA in terms of 
repigmentation. 
Mechanism of action: 
 By means of immuno modulation and stimulation of the melanocyte 
reserves in the hair sheaths, it produces repigmentation of vitiligo patch. 
77
 
 
ADVANTAGES 
• Since there is no oral intake like psoralen, no systemic side effects are 
noted. 
• It can be used in pregnancy and childhood.
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• Exposure time is shorter than PUVA. 
 
Duration of therapy: 
Given twice weekly has become the preferred therapy for vitiligo. If no 
response is observed after 6 months further therapy should be discouraged. 
Systemic corticosteroids: 
It can be used alone or in combination with topical agents for vitiligo 
mainly used in controlling the activity of the disease. 
 
Oral Mini Pulse therapy (OMP). 
 
 Smaller cyclical pulsed administration of corticosteroids mainly used for 
halting rapidly progressive vitiligo.
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It comprises of administering 5mg of betamethasone/dexamethasone 
with breakfast on two consecutive days in a week. For children, the dosage is 
0.5mgfor every 5kg of body weight. For those who do not respond to 5 mg/day,   
7.5 mg/day may be used, and then reduced to 5 mg/day if disease progression is 
arrested. 
OMP is not useful to repigment stable vitiligo patches. Optimal duration 
of therapy to stop vitiligo progression varies between 3 to 6 months. 
Oral prednisolone 10-40 mg/day for a period of 3months to 1 year and 
Systemic therapy with ACTH
80
 (25-40 IU IM twice a week) has been tried in 
vitiligo with good results 
KHELLIN (KUVA) 
 Khellin is extracted from the seeds of the plant Ammi visnaga. It is a 
furanochrome with a chemical structure closely resembling the psoralen family 
and having similar photobiological,photochemical and phototherapeutic 
properties.
81,82
 
Can be given at the dose of 50- 100 mg, two and half hours prior to 
exposure to sunlight. UVA can be given at the dose of 15 J /Cm2 .Side effects 
include a mild elevation of liver enzymes, nausea & orthostatic hypotension
83
 
and porphyria cutanea tarda.
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PHENYLALANINE 
 It is a natural, essential aminoacid and a precursor of tyrosine which is 
required for the synthesis of melanin. Prescribed dose is 50 mg/ kg body 
weight, 45 minutes prior to UV exposure twice a week. 
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CONTRAINDICATIONS 
•Phenylketonuria 
•Skin cancer 
•Impaired liver and renal function 
•Pregnancy 
•Lactation 
•Arsenic exposure 
 
Vitamins and Trace Elements: 
               2 mg of folic acid and 500 mg of vitamin C twice a day along with 
100 mg of vitamin B12 every 2 weeks administered intramuscularly showed 
significant repigmentation in patients of vitiligo.
86 
Vitamin C and E are used in 
vitiligo for its antioxidant property. 
 
Heliotherapy: 
              It is usually combined with treatments like topical steroids or ingestion 
of various vitamins. Exposure to the sun can be done with psoralens, 
melagenina, khellin and phenylalanine. The mode of action is unknown but it 
may re-establish the normal tyrosinase activity possibly by reducing serum 
copper level and plasma ceruloplasmin. 
87
  
ANAPSOS 
It is made of an extract of algae plant claimed to bring repigmentation in 
few patients of vitiligo.
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ANTIOXIDANTS 
Canthaxanthine 
 A food colouring agent used as a pigment to darken and to photo 
protects vitiliginous skin.
 89 
Intake can produce yellow deposits in the retina 
which have been seen to persists after 30 years of stopping the drug. 
Alfa Tocopherol  
 Combined with weak to moderate topical corticosteroids or PUVA. It 
has been proposed for treatment for vitiligo with little success.
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IMMUNOMODULATORS: 
• Cyclophospamide  
Given orally 50 mg twice a day.
 91 
It is not recommended for general use 
due to its adverse effects.  
• Meclorethamine: 
Can cause hyper pigmentation of the skin after topical application by 
increasing the number of melanocytes. 
• Levamisole: 
When given in a dose of 250mg for two consecutive days and every 
week for up to 48 months, was effective in controlling and reducing 
limited and slow spreading vitiligo.
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• TAR: 
Crude coal tar 300mg /ml was applied at weekly intervals to vitiligo 
macules and allowed to stay atleast for 3 hrs. 50% of patients found 
repigmentation after 10 to 30 cycles.
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OTHER SYSTEMIC AGENTS 
 
• Calcium pantothenate 100mg along with Para amino benzoic acid 
(PABA) 500mg twice daily may help in repigmentation of vitiligo 
patches and leukotrichia associated with vitiligo.
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• Dapsone 100mg/day found to be useful in segmental vitiligo. 
95 
It 
probably acts by immunomodulation. 
 
• Melatonin
96
 has been found effective in vitiligo. 
LASERS: 
• EXCIMER LASER 
308 nm xenon lasers is an effective and safe modality for the treatment 
of stable vitiligo given twice or thrice weekly for 10 to 15 sittings. 
• Ultrapulse CO2 laser used in association with PUVA therapy showed 
good results. 
97
 
 
 
Combination therapies: 
 
 Various combination therapies have been proved to be successful in the 
treatment of vitiligo. They are 
• PUVA  following surgical treatment  .
98,99
 
• NB-UVB with surgical therapies 
100,101   
 
• Punch grafting with topical steroids (fluocinolone acetonide o.1%)
102   
 
• Topical steroids with 308 nm excimer laser 
103
 particularly helpful in 
difficult to treat areas such as bony prominences. 
• Topical tacrolimus with NB-UVB 
104
 
• Oral antioxidants Polypodium leucotomos extract with NB-UVB. 
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Depigmenting therapy for extensive vitiligo: 
 
Indications: 
• In case of extensive vitiligo refractory to treatment. 
• To achieve a uniform appearance by removing islands of normal  
pigments in extensive vitiligo. 
20% Monobenzyl ether of hydroquinone in a cream base is applied to 
the remaining areas of pigmentation twice daily for 3-6 months. It produces a 
permanent depigmentation.
 
 
Topical 20% 4-methoxy phenol can also be used for depigmentation\ 
Cryotherapy : 
 Cryospray application over a period of some weeks or months can cause 
the residual pigment to disappear without complications can be used for small 
areas but the patient must be tolerant to the discomfort produced during 
procedure. 
 
 
SURGICAL MODALITIES FOR VITILIGO 
 
• Therapeutic wounding: Dermabrasion, Laser ablation,  LN cryosurgery, 
needling, Phenol or TCA application  
• Cosmetic tattooing. 
• Excision and closure 
• Tissue graft: 
1. Thin and ultra-thin split-thickness skin grafts (STSG) 
2. Suction blister epidermal grafts (SBEG) 
3. Mini-punch grafts (MPG) 
4. Hair follicular grafts (HFG) 
• Cellular  graft: 
1. Non-cultured epidermal cell suspension (NCES) 
2. Cultured “pure” melanocytes (CM) 
3. Cultured epithelial grafts (CE) 
4. Ultrasonic abrasion and seed grafts 
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5. Flip-top technique of grafting 
107
 
 Among all procedures, suction blister epidermal grafts, thin and ultra-thin 
split-thickness grafts seem to be the most effective procedure. Among cellular 
grafts, all techniques seem to be equally effective. 
 
5 Fluorouracil and Dermabrasion  
5 Fluorouracil: 
 It is a fluorinated pyrimidine antagonist which acts by interfering with 
DNA synthesis. Topical 5-fluorouracil (5-FU) has been used in clinical practice 
since 1960s. 
Mechanism of Action: 
                     It gets misincorporated in to RNA and disrupts its 
synthesis. The enzyme thymidilate synthetase is blocked by its metabolites thus 
interfering with DNA synthesis.   
            
Adverse effects:  
Localised :  
• Erythema, irritation ,burning ,pain, pruritus ,hypo and   
hyperpigmentation , and allergic contact dermatitis 
Systemic : 
       Systemic adverse effects are extremely rare with topical preparation.  
       The following adverse effects are noted with intravenous 5 FU 
• Nausea, anorexia and diarrhea. 
• Stomatitis, alopecia and myelosuppression. 
• Cardiac and neurologic toxicity.  
 
Unusual reactions: 
      This include onycholysis, onychodystrophy,and the appearance of 
telangiectasias. 
 
AVAILABLE PREPARATIONS: 
              Available as a 0.5, 1 %, 2 % or 5% cream and 1% solution & 5% 
solution. The solution can also be used for intralesional iniection. 
 
 
 
GENERAL THERAPEUTIC GUIDELINES FOR TOPICAL 5 
FLUOROURACIL 
 Usual treatment duration is for 2- 6weeks and it has to be avoided in 
areas like nasolabial folds, and eyes. Treatment is restricted to 2 weeks in case 
of lesions over the face. Its inflammatory property produces edema, erythema 
& pain .Topical corticosteroids can be used concomitantly with 5 FU to relieve 
inflammation. 
 
CLINICAL USE 
INDICATIONS 
• Actinic keratoses: 1 percent or 5 percent cream is FDA approved for 
treatment of actinic keratoses. 5-FU is used twice daily until an 
inflammatory response is seen, usually for 2 to 4 weeks. The 0.5% 
cream can be used once daily in case face and scalp lesions. 5 FU may 
also be a useful adjunct before cryosurgery of actinic keratoses. 
• Squamous cell carcinoma in situ: 5% 5fluorouracil applied twice daily 
for 4-6 weeks. 
• Porokeratosis: Found to be effective as once daily application without    
occlusion in treatment of multiple disseminated porokeratosis lesions
108,
 
• Verrucae vulgaris, verrucae plana, plantar warts, and condylomata 
acuminate can be treated with topical and intralesional 5-FU.  
 Intralesional 5-Fluorouracil can also be used in case of Psoriasis and 
keratoacanthomas, infantile digital fibromatosis, keloids and hypertrophic 
scars.
109, 110
 
 In addition, actinic cheilitis, mucosal leukoplakia, radiodermatitis, 
Bowendisease, Bowenoid papulosis, and erythroplasia of Oueyrat have all been 
reported to respond to treatment with topical 5-FU.  
             
5 Fluorouracil for vitiligo: 
Various Studies have demonstrated therapeutic efficacy of topical 5% 5-
FU, in the treatment of vitiligo with various success rates. 
111,112,113
 
 
Dermabrasion : 
In this technique skin is abraded with an abrasive tip with high speed 
rotary hand engine manually or mechanically, that may be either a wire brush 
or a diamond fraise creating a wound that heals by secondary intention.
  
 
History of the Procedure: 
The technique was first described by Kurtin in1953; he also described 
the use of high-speed rotary abraders, intraoperative freezing, and a variety of 
abrasive end pieces. Further refinement of this technique was done by 
Orentreich and Burks and Thomas.
 114,115 
Alt and Yarborough used the diamond 
fraise and wire brush respectively.
  
 
Mechanism of dermabrasion: 
 Dermabrasion removes the epidermis and papillary dermis thereby 
creating an open wound which heals by secondary intention. Stimulation of the 
inactive melanocytes at the outer root sheath of the hair following epidermal 
injury results in repigmentation in case of vitiligo. 
 
TYPES OF DERMABRADORS: 
They are of 2 types  
1. Manual dermabrador 
2. Mechanical dermabrador which uses either diamond fraise or wire brush 
to dermabrade the lesions. 
 
 
Indications: 
• Scars : Acne scars, post traumatic and surgical scars  
• Rhinophyma,  
• Deep rhytides 
• Actinic Keratoses, 
• Seborrheic keratosis. 
• Angiofibromas,  
• Syringomas 
• Epidermal nevi,  
• Stable Vitiligo 
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• Pigmentary disorders like melasma,freckles,melanosis ,  
• Tattoo removal.  
• Hyperkeratotic  lesions like lichen simplex chronicus,hypertrophic 
lichen planus, and lichen amyloidosis 
Contraindication: 
• Active herpetic lesions. 
• Isotretinoin Therapy within 6-12 Months before procedure. 
• Bleeding disorders. 
• Immuno compromised  individuals. 
 
 
 
 
Preoperative evaluation:  
Before starting the procedure one should look for patient’s skin type,  
history of koebnerization, psychological status, history of keloidal tendency,  
systemic illness like diabetes to have better outcome. 
 
Patient should be explained about the treatment, advantages, 
disadvantages and most importantly the realistic outcome of the procedure. 
 
Clinical photographs taken before and after the procedure can be used as 
a tool to measure the improvement. 
 
 
Role of Dermabrasion in vitiligo: 
 
  It can be used as a part of management of vitiligo in combination with 
other techniques.  
 
• Epithelial sheet grafting  following dermabrasion can be done.
117,118
 
 
• Dermabrasion followed by thiersch grafting can induce repigmentation. 
 
• Can  be used in conjunction with thin split thickness skin grafting  for 
effective repigmentation.
119,120
 
 
• It can be used before transplantation of non cultured melanocytes.
121,122
 
 
Disadvantage: 
• Mainly operator dependent. 
• Depth of penetration cannot be judged easily. 
 
 
 
 
 
Complications: 
• Transient, postoperative hyperpigmentation, usually seen 4-6 weeks 
after dermabrasion.  
• 1/3 of patients develop hypopigmentation. 
• Scar formation.  
• Secondary Infections 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Aim of the Study 
AIM OF THE STUDY 
               The aim of the study is to evaluate the efficacy of dermabrasion with 
topical 1% 5-fluorouracil in patients with stable vitiligo patches and to assess 
the feasibility of this procedure in day to day practice.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Methodology 
MATERIALS AND METHODS 
    This was a one year, open, prospective, study conducted in vitiligo 
patients attending Department of Dermatology, Coimbatore Medical College         
Hospital, Coimbatore. This study was conducted from June 2010 to June 2011. 
The procedure of dermabrasion  with topical 5 fluorouracil was done for the 
patients  within  the first  6 months with follow up of the patient for next 6 
months. 
 
Twenty five patients, men and women, 15-60 years of age with clinical 
diagnosis of stable vitiligo of more than 2 year duration were eligible for 
enrollment in the study.   
 
 Name, age, sex, marital status, occupation, and residential address of 
the patients were noted. 
 
A detailed history regarding the onset, duration and course of the 
disease, presence or absence of precipitating factors, family history, associated 
skin and systemic problems, treatment taken so far and its outcome were 
recorded. Dermatological assessment carried out mainly for the presence of 
white hairs. 
 
INCLUSION CRITERIA 
• Patients of both sexes. 
• Age group between 15-60 years. 
• Stable patches of vitiligo more than 2 year duration. 
 EXCLUSION CRITERIA 
• Mucosal vitiligo, unstable vitiligo, actively spreading vitiligo  
• Vitiligo less than 2 year duration. 
• Children less than 12 years of age. 
• Pregnant and lactating women. 
• Diabetic patients.  
• Patient currently under other topical or systemic therapy for vitiligo. 
• Patients with keloidal tendency 
• Patients with Bleeding Diathesis. 
• H/o koebner phenonmenon. 
• Vitiligo involving the face. 
PRE OPERATIVE WORK-UP: 
       Once the criteria was satisfied informed written consent were obtained 
from the patient after explaining about the post procedure sequelae, side effects 
and complication. Screening for HIV was done in all patients in addition to 
complete hemogram, blood sugar, bleeding and clotting profile. Consent was 
obtained for taking photographs and they were instructed to come for regular 
follow-up. 
PROCEDURE 
A stable vitiligo patch was selected. Patch and the surrounding area 
were cleaned with spirit & povidone iodine solution, allowed to dry.  2% 
lignocaine injection was give intra dermally , after 10 mins of lignocaine 
infiltration , a hand held manual  metallic dermabrador  was used to 
dermabrade the patch initially in a to and fro motion, followed by horizontal 
and longitudional criss cross strokes, until pin point bleeding is seen in the 
patch. Surrounding skin within 1 cm area of the patch is also dermabraded to 
prevent recurrence.  1% 5-fluoruracil cream was applied over the patch to form 
a thin layer.  Dermabraded site was closed with gauze and dressing done. 
Patient was given systemic antibiotic for next 7 days and dressing was 
removed at the end of third day of the procedure. Patient was followed up at the 
end of every month for the next 6 months to look for repigmentation. 
Photographs were taken before the procedure as well as during the 
follow up period. Any adverse effect during the study was recorded with 
importance to infection, pain & scarring. 
Repigmentation was taken as, 
• Complete  repigmentation when it  was 100%  and any  
percentage of pigmentation < 100 was taken as partial 
repigmentation   
  
 
 
 
 
 
 
 
 
 
 
Observation and Results 
 
OBSERVATION AND RESULT 
 Erythema pain and exudation over the abraded site has been noted for 
first 4-7 days in all the patients. After 1 week the patients were free from 
discomfort and pain. Perifollicular pigmentation has been noted at the end of 
first month in most of the patients. Secondary infection has been noted in only 
one patient that cleared after 1 week, after treating with antibiotics. Hyper 
pigmentation with scarring has been observed in three patients. At the at the 
end of 6 months out of 25 patients 4  did not turn for follow up. Partial 
repigmentation  was observed  in  six patients (28.6%) and  total 
repigmentation  in fifteen patients (71.4%) .Of this complete repigmentation 
was  seen at the end of third month in  7 patients &  at the end of sixth month  
in 8 patients.      
 
No of 
patients 
enrolled 
No of 
patients 
came for 
regular 
follow up 
No of patients 
showed 
complete 
repigmentation 
No of patients 
with partial 
repigmentation 
No of 
dropouts 
Adverse effects noted 
25 21 15 (71.4%) 06 (28.57%) 04 
Repigmentation 
noted were 
darker than 
normal skin in 
13 patients 
(61.9%) 
Superficial 
scar  noted in 
3(14..28 %) 
patients along 
with 
repigmentation 
Secondary 
Infection  
noted in 1 
patient 
Pain  at  adraded 
site  for  a week 
noted  in all 
21(100%)Patients 
 
 
REPIGMENTATION
partial 28.6%
complete 71.4%
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Discussion 
DISCUSSION 
Dermabrasion with topical 5 fluorouracil was first used in vitiligo 
patients in 1983. It creates an epidermal injury that results in loss of integrity of 
the epidermis leading  to  stimulation of the  inactive melanocytes at the outer 
root sheath of the hair which proliferate  and migrate upwards and start 
synthesizing melanin at the infundibulum, from there they migrate and reach 
the surface of the skin that presents as perifollicular pigmentation , which 
enlarges to cover the depigmented area.  Only pigmented hair acts as 
melanocytes reservoir for repigmentation hence the technique will not be useful 
in  vitiligo patches with white hair.
123,124
 
 
 
 Once the epidermis has been removed, by applying topical 5 
fluorouracil, an irritation is mediated that induce production of inflammatory 
cytokines and prostaglandins, which stimulate melanocyte migration and 
proliferation. 
 
Two hypotheses postulated for fluorouracil induced repigmentation of  
vitiligo lesions are 
125,126
 
 
1. It stimulates the division of epidermal melanocytes that migrate into the 
affected areas after epithelialization of the epidermis or the melanocytes 
may be derived from the hair follicles 
 
2. It competes with desoxyuridine and its derivatives for the enzyme 
thymidylate synthetase which is a potent inhibitor of a variety of cellular 
activities and kills some inhibitory agent or cells within the epidermis or 
dermis that were responsible for the destruction of the melanocytes 
causing vitiligo. 
 
  Repigmentation usually begins within two weeks after complete 
epithelialization of the wound. Only patients with stable disease and limited 
extension of the manifestations can be treated with this technique. 
 
In our study complete repigmentation was seen in 15 patients out of 21 
with 71.4% success rate for this procedure. A study  done by Sethi                       
et al  comparing dermabrasion,  dermabrasion with topical 5% 5-fluorouracil 
dressing, and dermabrasion with a topical placentrex gel,  showed                     
higher efficacy (73%) for the combined  treatment  of dermabrasion with                          
5- fluorouracil.
127
 
 Various studies have been done with either 5 fluorouracil or 
dermabrasion  as well combination of both, in one study the effect of topical 5 
fluorouracil ointment along with epidermal abrasion showed 81.5% success 
rate with dermabrasion along with 5 fluorouracil, 20.4% for topical 5 
fluorouracil alone and 7.4% for dermabrasion alone .
128
  
 In our study 1% 5 fuorouracil cream was used while in previous studies, 
it was 5 % cream and therefore the severity of inflammation & side effects 
were minimal in our study. 
 In  most of the previous studies,  topical 5 fluorouracil  was applied 
daily  for a week ,whereas in our study it was applied for a  short  duration of  3 
days   under occlusion.  
ADVANTAGES OF THIS PROCEDURE: 
1. Single shot therapy. 
2. Except for post procedure pain and discomfort no significant 
complications were noted in most of the patients. 
3. Patient acceptance was good 
4. Early repigmentation within 3 months of therapy. 
5. Cost effective  
LIMITATION OF THIS STUDY:  
1. Small sample size  
2. Repigmentation achieved were darker compared to normal skin but 
patient acceptance was good 
3. It works only for stable vitiligo. 
4. Not useful in mucosal,  lip tip and  acrofacial vitiligo  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
CONCLUSION 
Among various surgical modalities available for vitiligo, dermabrasion 
along with 5 fluorouracil can   be used as a simple office procedure, in 
repigmenting focal and to a lesser extent generalized stable vitiligo, which is 
very economical & brings early repigmentation without any significant side 
effects, which can allay the anxiety & stigma of the patients and brings back 
smile in their faces. 
 
 
                                         
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proforma 
PROFORMA 
NAME: 
Age : 
Sex : 
Address: 
Occupation : 
Clinical history: 
Duration: 
Family History : 
H/o Diabetes: 
H/o Bleeding tendancy: 
H/o keloidal  tendancy : 
H/o suggestive of Koebner phenomenon :  
Investigations: 
Complete hemogram: 
Blood  
             Urea: 
             Sugar:  
             Creatinine: 
Bleeding time: 
Clotting time: 
  
 
 
 
 
 
 
 
 
 
 
Consent Form 
 
Consent form  
 
 
Hospital:                                                              Op number: 
 
Patient name:                                                       Age/Sex: 
 
Consent for surgical procedure: 
 I have been explained in language that I understand the nature of 
procedure, its expectected benefits, possible side effects and after effects and 
the risk involved. 
 After understanding all this things stated above I agree to undergo the 
above mentioned procedure.  
 
Date:                                                                           Signature of the patient                                       
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